About BillionToOne
BillionToOne is a publicly listed company based in San Francisco (United States) founded in 2015 by Oguzhan Atay and Sukrit Silas. Provider of cell-free cancer liquid biopsy test. BillionToOne has raised $388.62 million across 10 funding rounds from investors including IDrive, HHS and Baillie Gifford. The company has 861 employees. BillionToOne was last valued at $2.4 billion in November 2025. Its chief executive, as recorded, is Oguzhan Atay. Its website billiontoone.com draws about 27 thousand monthly visits. BillionToOne offers products and services including UNITY Screenâ„¢, Northstar Selectâ„¢, and Northstar Responseâ„¢. Its focus areas include Life Sciences, Women Health, In Vitro Diagnostic Tests and Prenatal. Its legal entity is BillionToOne Inc. Its competitors include Guardant Health, GRAIL and Natera; 3 of its 3 listed competitors have raised funding.
Company details
BillionToOne was founded in 2015 in San Francisco, United States, within the biotechnology sector. Cell-free cancer liquid biopsy tests are offered, supported by a molecular counter platform that analyzes DNA molecules from blood samples. Additional genetic tests are provided for conditions including cystic fibrosis, spinal muscular atrophy, and sickle cell disease. Operations center on diagnostic services for oncology and inherited disorders.
- Headquarters San Francisco, United States
- Employees 861
- Founders Oguzhan Atay, Sukrit Silas
- Stage Public
- SectorsHealthcare
- Website category Computers Electronics and Technology · Graphics Multimedia and Web Design
- Website billiontoone.com
- Social LinkedIn X
- Legal Name Billiontoone, Inc.
- Total Equity Funding$388.62M (USD)
in 10 rounds
- Latest Funding Round$130M (USD), Series D
Jun 2024
- InvestorsIDrive
& 34 more
- Employee Count861
Products & Services of BillionToOne
BillionToOne offers a comprehensive portfolio of products and services, including UNITY Screen™, Northstar Select™, and Northstar Response™.
Assesses fetal risk for recessive conditions and aneuploidies using maternal blood.
Determines appropriate first-line therapy for cancer patients.
Monitors effectiveness of cancer therapies through testing.
Funding Insights of BillionToOne
BillionToOne has successfully raised a total of $388.62M across 10 strategic funding rounds. The most recent funding activity was a Series D round of $130 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $388.62M
- Total Rounds 10
- Last Round Series D — $130M
- First Round $120,000
(Jun 2017)
- Investors Count 35
All 10 funding rounds of BillionToOne with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2024 | $130M | Series D | – | Premji Invest | |
| Dec 2022 | $48.5M | Series C | – | Baillie Gifford, Adams Street Partners | |
| Dec 2022 | Debt – Conventional | – | – | ||
| Mar 2022 | $125M | Series C | – | Adams Street Partners, Hummingbird Ventures | |
| Mar 2022 | Series B | – | 500 Global | – | |
| Jun 2021 | $55M | Series B | – | Four Rivers Group, Hummingbird Ventures | |
| Mar 2020 | $15M | Series A | – | Hummingbird Ventures, Neotribe | |
| Mar 2019 | $15M | Series A | – | Hummingbird Ventures, Neotribe | |
| Sep 2018 | $217,790 | Grant | – | – | |
| Jun 2017 | $120,000 | Seed | – | Y Combinator | – |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of BillionToOne
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $2.4B (Nov 2025). 35 investors in total: 35 institutional.
Investors in BillionToOne
BillionToOne has secured backing from 35 investors, including venture fund and institutional investors. Prominent investors backing the company include IDrive, HHS and Baillie Gifford.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides venture capital for technology startups and enterprise innovations worldwide. | premjiinvest.com | Bengaluru, India | ||
Secondary market fund focused on LP and direct secondary transactions | 1993 | nb.com | New York, United States | |
Private markets investment management with strategies in equity, credit, and secondary investments. | adamsstreetpartners.com | |||
Investments in early-stage startups are focused on by Hummingbird Ventures. | hummingbird.vc | London, United Kingdom | ||
Venture capital is provided to health tech and biology innovations. | civilizationventures.com | San Francisco, United States | ||
Early-stage blockchain investments are managed by Libertus Capital. | libertuscapital.com | London, United Kingdom | ||
Venture capital firm focused on multiple sectors | fiftyyears.com | San Francisco, United States | ||
Venture capital firm focused on tech sectors | neotribe.vc | Menlo Park, United States | ||
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors. | 1961 | nvp.com | Menlo Park, United States | |
Venture capital firm focused on life science and healthcare sectors | timebioventures.com | California City, United States |
Investor details for BillionToOne
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BillionToOne
161 people are tracked at BillionToOne (35 in leadership, 3 in board & advisors, 123 in team); the tracked headcount is 861.
| Name | Role | Group |
|---|---|---|
Oguzhan Atay | Co-Founder & CEO | Leadership |
Sukrit Silas | Founder | Leadership |
Carrie McGehee | VP, Market Access | Leadership |
Matthew Varga | Associate Director, Clinical Affairs | Leadership |
Michele Phelps | Director, Financial Planning & Analysis | Leadership |
John Ten Bosch | Senior Vice President Of Lab Operations | Leadership |
David Tsao | Co-Founder & CTO | Leadership |
Devon Chandler-Brown | Associate Director Of Development, Prenatal | Leadership |
Gemma English | VP, Reimbursement | Leadership |
Gary Palmer | Chief Medical Officer, Oncology | Leadership |
Vaghar Haghiri | Senior Director, People Operations | Leadership |
Karel Hurka | Senior Director, Supply Chain | Leadership |
Jay Chang | Director of Medical Partnerships | Leadership |
Michelle Nguyen | Associate Director, People Operations | Leadership |
Jonathan Stumpf | Director of Market Access | Leadership |
Brittany Williams | Area Director, East | Leadership |
Brandon Resendez | Area Director, West | Leadership |
Joanna Bradley | Director, Talent Acquisition | Leadership |
Brent Kirk | Senior Director, Sales Strategy & Operations | Leadership |
Jennifer Hoskovec | Senior Director, Medical Affairs | Leadership |
141 more people are available in the full profile.
Complete people profiles for BillionToOne
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BillionToOne
BillionToOne is a publicly listed company on the NASDAQ with ticker symbol BLLN in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date06 Nov 2025
- Listed onNASDAQ: BLLN
- Listed entityBillionToOne, Inc.
- Exchange sectorHealth services
- ISINUS0901681058
- Share price$94.44 (+1.47% on the day) · 2026-10-13
- Market capitalisation$4.46B
- Price to earnings153.3
- EPS (diluted, trailing year)$0.62
- Volume (last session)664,221
Timeline of BillionToOne
5 dated milestones of BillionToOne across 10 years, from founding to its latest funding, stage changes and deals.
- Founded BillionToOne is founded.
- Funding First funding round of $120K.
- Funding Latest funding round, Series D, of $130.0M.
- Milestone Reaches Unicorn status.
- IPO Lists on the stock exchange (IPO).
Competitors of BillionToOne
BillionToOne has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Natera.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health |
Detailed competitors of BillionToOne
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BillionToOne
The website of BillionToOne (billiontoone.com) receives about 26.8K visits a month and ranks #1,175,108 among all websites worldwide, #10,669 in Graphics Multimedia and Web Design.
- Monthly visits26.8K
▲ 8.1% vs previous month
- Unique visitors11.4K
per month
- Global rank#1,175,108
among all websites
- Category rank#10,669
Computers Electronics and Technology · Graphics Multimedia and Web Design
- Bounce rate44%
- Pages per visit1.8
- Average visit26 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with BillionToOne. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| linkedin.com | 100% | 1.9B | #18 | View details | |
| google.com | 95% | 85.8B | #1 | View details | |
| reddit.com | 95% | 4.4B | #9 | View details | |
| github.com | 77% | 542.6M | #65 | View details | |
| facebook.com | 77% | 12.1B | #3 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for BillionToOne
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as BillionToOne (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Billiontoone
Complete news archive for BillionToOne
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BillionToOne
BillionToOne was founded in 2015 and raised its 1st funding round 2 years after it was founded.
BillionToOne is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Oguzhan Atay is the CEO of BillionToOne, as recorded in our data. They have also founded this company.
BillionToOne is a funded company, having raised a total of $388.62M across 10 funding rounds to date. The company's 1st funding round was a Seed of $120K, raised on Jun 2017.
BillionToOne has 861 employees.
BillionToOne was founded in 2015 in San Francisco, United States, within the biotechnology sector. Cell-free cancer liquid biopsy tests are offered, supported by a molecular counter platform that analyzes DNA molecules from blood samples. Additional genetic tests are provided for conditions including cystic fibrosis, spinal muscular atrophy, and sickle cell disease. Operations center on diagnostic services for oncology and inherited disorders.
BillionToOne's top competitors include Guardant Health, GRAIL and Natera.
BillionToOne offers UNITY Screenâ„¢, Northstar Selectâ„¢, and Northstar Responseâ„¢.
Yes, BillionToOne is publicly traded on NASDAQ under the ticker symbol BLLN.
BillionToOne has 35 investors. Key investors include IDrive, HHS, Baillie Gifford, Bridge Community Bank, and Neuberger Berman.
The valuation of BillionToOne is $2.4B as of Nov 2025.
BillionToOne operates through Billiontoone Inc.